Third Harmonic Bio (THRD) Q1 2025 earnings summary

Executive summary

• Announced a Plan of Dissolution, with board approval to liquidate and distribute remaining cash to stockholders, pending shareholder vote in June 2025.

• Restructuring in February 2025 included halting all non-THB335 R&D and a 50% workforce reduction to preserve capital.

• THB335 Phase 1 trial completed; company intends to complete Phase 2 readiness and seek asset sale before dissolution.

• Estimated initial distribution to shareholders is $5.13–$5.33 per share, with total distributions potentially up to $5.42 per share.

• No products approved or revenue generated; focus remains on maximizing value from THB335 and cash reserves.

Financial highlights

• Net loss for Q1 2025 was $15.8 million, up 102% from $7.9 million in Q1 2024.

• Operating expenses rose to $18.7 million in Q1 2025 from $11.3 million in Q1 2024, driven by THB335 development and restructuring costs.

• Cash and cash equivalents totaled $271.6 million as of March 31, 2025.

• Accumulated deficit reached $175.5 million as of March 31, 2025.

• No revenue recognized; all funding from equity offerings and IPO proceeds.

Outlook and guidance

• If dissolution is approved, company expects to file for dissolution in Q3 2025 and delist from Nasdaq.

• Existing cash expected to cover all obligations and provide for shareholder distributions; further asset sale proceeds could increase distributions.

• Company will maintain reserves for liabilities and contingent claims as required by Delaware law.

• Board retains right to abandon dissolution if circumstances change.

• No guidance on future product development or commercialization beyond THB335 asset sale.